EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Aloperine Suppresses the Tumorigenicity of Esophageal Squamous Cell Carcinoma by Targeting the AP-1/IL-6/STAT3 Signaling Axis

Ba-Fang Ma, Jun-Nan Ye, Die Bai, Chang Ge, Yingchao Guan, Yang Lou, Ya-Ping Liang, Na Bu, Wenhui Hao, Yasen Maimaitiyiming iD

Biomolecules · 27.05.2026 · 16 (6) · 791

DOI: 10.3390/biom16060791 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, online erschienen am 27.05.2026. Verfasst von Ba-Fang Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi 830011, China. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Interleukin-6, Esophageal Squamous Cell Carcinoma, Transcription Factor AP-1. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Xinjiang Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with a poor prognosis, largely due to therapeutic resistance and the limited availability of effective targeted therapies. Aloperine (ALO), a natural alkaloid derived from Sophora alopecuroides L., exhibits anti-cancer properties in various tumor types; however, its therapeutic potential and underlying mechanism in ESCC remain unclear. Here, we report that ALO inhibited ESCC cell proliferation and colony formation in a dose- and time-dependent manner and induced caspase-dependent apoptosis, accompanied by loss of mitochondrial membrane potential and PARP1 cleavage. Mechanistically, ALO significantly suppressed inflammatory pathways, with IL-6 identified as a critical downregulated target. ALO inhibited IL-6 production by targeting the AP-1 transcription factor complex, as evidenced by reduced cFOS expression and suppressed cJUN phosphorylation. Consequently, ALO inhibited downstream IL-6/JAK-STAT3 signaling. Functionally, exogenous IL-6 rescued ALO-induced loss of cell viability. Notably, the combination of ALO with cisplatin exerted synergistic antitumor effects. In a syngeneic mice model, the combination therapy significantly reduced tumor growth and Ki67 expression while inducing apoptosis, as shown by increased TUNEL staining and cleaved caspase-3 expression, and further suppressing the IL-6/STAT3 axis compared with either monotherapy. Together, these findings demonstrate that ALO exerts potent anti-ESCC activity by targeting the AP-1/IL-6/STAT3 signaling axis. The synergistic efficacy of ALO with cisplatin highlights its potential as a promising therapeutic agent to overcome chemoresistance and improve outcomes in ESCC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT3 Transcription FactorInterleukin-6Esophageal Squamous Cell CarcinomaTranscription Factor AP-1Esophageal NeoplasmsPiperidinesHumansAnimalsSignal TransductionMiceCell Line, TumorQuinolizidinesApoptosisCell ProliferationQuinolizidine AlkaloidsMaleCisplatin

Stichwörter der Autor:innen

AP-1 transcription factorAloperineIL-6/STAT3 signalingapoptosisesophageal squamous cell carcinoma

Substanzen

STAT3 Transcription FactorInterleukin-6Transcription Factor AP-1aloperineQuinolizidinesPiperidinesSTAT3 protein, humanQuinolizidine AlkaloidsCisplatin

Autor:innen und Institutionen

  • Department of Immunology, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi 830011, China.
  • Xinjiang Key Laboratory of Molecular Biology for Endemic Diseases, Xinjiang Medical University, Urumqi 830011, China.
  • Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi 830011, China.
  • Department of Pharmacy, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310058, China.
  • Institute of Basic Medical Sciences, School of Basic Medical Sciences, Xinjiang Medical University, Urumqi 830011, China.

ORCID-Profile: Yasen Maimaitiyiming

Förderung

  • National Natural Science Foundation of China
  • State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia
  • Xinjiang Medical University
  • Xinjiang Uygur Autonomous Region Tianchi Talent Introduction Program

Zitieren

APA

Ma, B. F., Ye, J. N., Bai, D., Ge, C., Guan, Y., Lou, Y., Liang, Y. P., Bu, N., Hao, W., & Maimaitiyiming, Y. (2026). Aloperine Suppresses the Tumorigenicity of Esophageal Squamous Cell Carcinoma by Targeting the AP-1/IL-6/STAT3 Signaling Axis. Biomolecules, 16(6), 791. https://doi.org/10.3390/biom16060791

Vancouver

Ma BF, Ye JN, Bai D, Ge C, Guan Y, Lou Y, et al. Aloperine Suppresses the Tumorigenicity of Esophageal Squamous Cell Carcinoma by Targeting the AP-1/IL-6/STAT3 Signaling Axis. Biomolecules. 2026;16(6):791. doi:10.3390/biom16060791

BibTeX
@article{Ma2026,
  author = {Ma, Ba-Fang and Ye, Jun-Nan and Bai, Die and Ge, Chang and Guan, Yingchao and Lou, Yang and Liang, Ya-Ping and Bu, Na and Hao, Wenhui and Maimaitiyiming, Yasen},
  title = {Aloperine Suppresses the Tumorigenicity of Esophageal Squamous Cell Carcinoma by Targeting the AP-1/IL-6/STAT3 Signaling Axis},
  journal = {Biomolecules},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {791},
  doi = {10.3390/biom16060791}
}
Kostenlos starten →